Roche Takes Genentech
Roche’s $46.8 billion takeover of Genentech (DNA) will give the Swiss company control of Avastin and Herceptin  promising cancer treatments. The bet: Results on Avastin’s clinical trials for early stage colorectal cancer will be released soon and if the drug is effective it would drive up Genentech’s value. Roche apparently believes the results will be positive and therefore rushed to complete the deal. Avastin is already approved to treat breast and lung cancer. It generated about $4.8 billion in sales last year and could become a top-selling drug worldwide. In terms of market share the combined company will be ...
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here